Retatrutide, a new dual agonist of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) receptor , is demonstrating promising outcomes in preliminary patient trials . Current inquiry https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/